J&J Is Short of Cancer Drug Doxil

Johnson & Johnson is warning doctors not to start new patients on its cancer drug Doxil due to a supply shortage — the latest in a series of shortages from various drug makers that have hamstrung health-care providers.
The Wall Street Journal